The number of people with susceptibility test result for rifampicin in Netherlands
Netherlands: The number of people with susceptibility test result for rifampicin was 86.26 in 2021. ▼ Falling
Latest (2021)
86.26
Change on year
down 1.4%
World rank
82nd
of 146 countries
All-time high
99.16
in 2017
All-time low
80.85
in 2019
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in Netherlands, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
Netherlands recorded 86.26 for the number of people with susceptibility test result for rifampicin in 2021.
That represents a change of down 1.4% on the previous year and down 13.0% over five years.
Netherlands ranks 82nd of 146 countries on this measure, in the middle of the range.
The number of people with susceptibility test result for rifampicin in Netherlands, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 99.16 | — |
| 2018 | 86.93 | -12.3% |
| 2019 | 80.85 | -7.0% |
| 2020 | 87.46 | +8.2% |
| 2021 | 86.26 | -1.4% |
Netherlands compared with similar countries
- Netherlands's 86.26 is below the median for high income countries, which is 92.6, 93% of the median. (56 countries reporting)
- Netherlands's 86.26 is below the median for Europe & Central Asia, which is 93.52, 92% of the median. (43 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 88.98 | 80.85 | 99.16 | 3 |
| 2020s | 86.86 | 86.26 | 87.46 | 2 |
Countries ranked near Netherlands
More health data for Netherlands
- Un projection of annual infant deaths, annual growth rate -2.44 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.1866 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,235 deaths per 1,000 people (2090)
- Number of infants who die before age 1 80 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate 0.4989 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0239 units per person (2025)
- Population ages 00-04, male, annual growth rate 0.5005 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in Netherlands?
- The number of people with susceptibility test result for rifampicin in Netherlands was 86.26 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in Netherlands?
- The highest recorded value was 99.16 in 2017.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in Netherlands?
- The lowest recorded value was 80.85 in 2019.
- How does Netherlands rank for the number of people with susceptibility test result for rifampicin?
- Netherlands ranks 82nd out of 146 countries with data for 2021.
- Where does this Netherlands data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).